Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

3 trials in Phase 3/4

Results Transparency

44%

4 of 9 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 4

3(50.0%)

N/A

2(33.3%)

Phase 2

1(16.7%)

6Total

Phase 4(3)

N/A(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT02490943Not ApplicableCompleted

A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in MS

Role: lead

NCT01356940Phase 4Completed

A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis

Role: lead

NCT02750982Not ApplicableCompleted

Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.

Role: lead

NCT01834586Phase 4Completed

Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications

Role: lead

NCT02369224Completed

Multicenter Validation of The Evergreen Myometric Strength Test for Lower Extremities (EMST-LE) in Multiple Sclerosis: Protocol for Strength Testing and Reliability Characteristics

Role: lead

NCT00457730Phase 2Completed

A Study to Test the Use of Duloxetine for Pain in MS

Role: lead

NCT01454791Phase 4Completed

Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate

Role: lead

NCT01749943Completed

Validation of Hand Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis

Role: lead

NCT00424359Completed

Ambulation Study in Multiple Sclerosis

Role: lead

All 9 trials loaded